Design, synthesis and biological evaluation of novel 3C-like protease inhibitors as lead compounds against SARS-CoV-2.

The epidemic caused by SARS-CoV-2 swept the world in 2019. The 3C-like protease (3CLpro) of SARS-CoV-2 plays a key role in viral replication, and its inhibition could inhibit viral replication. The virtual screen based on receptor-ligand pharmacophore models and molecular docking were conducted to obtain the novel scaffolds of the 3CLpro. The molecular dynamics simulation was also carried out. All compounds were synthesized and evaluated in biochemical assays. The compound could inhibit 3CLpro with a 72% inhibitory rate at 10 μM. The covalent docking showed that could form a covalent bond with the Cys145 in 3CLpro. could be a potent lead compound of 3CLpro inhibitors against SARS-CoV-2.